Pennsylvania company plans to land rover on moon: ‘This is how we lead,' Fetterman said
PITTSBURGH, Pa. (WTAJ) — A Pennsylvania robotics company aims to put a robotic rover on the moon by the end of the year and U.S. Senator John Fetterman said he fully supports the mission.
The company wants to 'FLIP' — FLEX Lunar Innovation Platform — as part of Astrobotic's Griffin Mission One (Griffin-1). Venturi Astrolab (Astrolab) and Astrobotic announced that the Griffin lander will put the Astrolab rover on the moon's south pole. It's scheduled to land by the end of 2025 as part of NASA's Commercial Lunar Payload Services (CLPS).
'Astrobotic received worldwide interest from dozens of organizations eager to fly aboard Griffin-1, and we conducted a rigorous selection process to identify the mission partner that aligned best with our timeline and Griffin's capabilities,' Astrobotic's founder and CEO John Thorton said in a release.
UAE announces groundbreaking mission to asteroid belt, seeking clues to life's origins
What was originally supposed to be NASA's VIPER, the organization scrapped plans due to cost and budget restrictions, however, they contracted out their plans for a lunar rover.
'Losing VIPER could've been a setback, but Astrobotic didn't let up. They rolled up their sleeves, found a new way forward, and made sure this mission stayed on track. With Astrolab's FLIP rover onboard, we're showing the world that when challenges come our way, we double down,' U.S. Senator John Fetterman said in the release.
FLIP is meant to land at the lunar south pole and demonstrates functions similar to the company's FLEX rover which was revealed in 2022.In 2023, Astrolab announced an agreement with Elon Musk's SpaceX to help land the lunar rover on the moon by the end of 2025.
'This is how we lead—not by playing it safe but by pushing forward with the technology that'll shape the future of exploration. I couldn't be prouder that Pennsylvania's Astrobotic is making sure America stays first in line to the lunar South Pole,' Fetterman added.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
25 minutes ago
- UPI
CPAP or Zepbound? Patients, doctors debate sleep apnea treatment
Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. Adobe stock June 9 (UPI) A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. The machines keep airways open using mild air pressure provided through a mask patients wear while sleeping. But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness data of CPAP versus tirzepatide, and a potential mismatch between patient and provider preferences when managing comorbid obesity and obstructive sleep apnea," lead researcher Ahmed Khalaf said in a news release. He's a sleep technician in the pulmonary, critical care and sleep medicine division at University of California-San Diego. Nearly 30 million adults in the United States have sleep apnea, a disease in which the upper airway collapses during sleep, causing people to wake repeatedly. CPAP has been considered the gold standard for treating sleep apnea, but some patients find the machines too bulky and noisy. About 50% of people prescribed CPAP either can't use it often enough to matter or find it too bothersome, according to Harvard Medical School. Common problems include mask discomfort, dry mouth, breathing that feels out of sync and noise from the machine. Late last year, the U.S. Food and Drug Administration approved Zepbound as the first drug to treat people with obesity and sleep apnea. At the time, the sleep medicine society hailed the approval as "a positive development for patients and clinicians, who now have another treatment option for this sleep disorder," according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem. For the new study, researchers analyzed nationwide online survey data from 365 patients, and also spoke to 17 sleep medicine professionals at UCSD. Doctors favored CPAP over Zepbound 53% to 26%, while patients favored Zepbound over CPAP 48% to 35%. Both doctors and patients supported treatment that combined CPAP and Zepbound, but doctors were more enthusiastic about combination therapy, 88% versus 61%. The patients' preferences are likely driven by their own experiences -- 78% said they were either current or former users of CPAP, results show. By comparison, only 23% of patients said they'd ever used Zepbound or Ozempic (semaglutide), the other prominent GLP-1 drug. Principal investigator Dr. Chris Schmickl, an assistant professor of medicine at University of California-San Diego, expressed surprise at the level of disagreement between patients and providers. "Recognizing differing attitudes toward treatment is crucial for developing a realistic and achievable action plan," he said in a news release. "Additional research to understand the underlying reasons behind these preferences will offer valuable insights for providers to guide treatment decisions." Researchers are scheduled to present these findings Wednesday at the society meeting in Seattle. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. More information Harvard Medical School has more on managing CPAP problems. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
an hour ago
- Yahoo
Axiom private mission to ISS delayed because of weather
June 9 (UPI) -- SpaceX, NASA and Axiom Space postponed Tuesday's scheduled launch of the fourth private astronaut mission to the International Space Station because of unfavorable weather conditions in the Dragon spacecraft's flight path. The Axiom Mission 4 launch had been scheduled for 8:22 a.m. Tuesday from the Kennedy Space Center's pad 39A, NASA said in a news release Monday. They now are targeting 8 a.m. EDT on Wednesday for the next launch opportunity. The backup opportunity is 7:37 a.m. Thursday. Axiom Space and SpaceX are planning coverage and NASA separately in the morning. Falcon 9's first stage would land on Landing Zone 1 at Cape Canaveral Space Force Station. This is the first flight for the Dragon spacecraft and second for the first-stage booster, which previously launched a Starlink mission The targeted docking time is one day later. There are nine people currently on the ISS. Peggy Whitson, 65, a former NASA astronaut and director of human spaceflight at Axiom Space, will command the commercial mission. The crew also includes pilot Shubhanshu Shukla with the Indian Space Research Organization, and mission specialists with the European Space Agency, Sławosz Uznański-Wiśniewski of Poland and Tibor Kapu of Hungary. This would be the first time ISRO will send an astronaut to the space station as well as ESA astronauts from Hungary and Poland. The crew members plan to conduct 60 scientific experiments and demonstrations "focused on human research, Earth observation, and life, biological, and material sciences," according to SpaceX. Axiom Space, which is based in Houston and founded in 2016, is building the first commercial space station with deployment planned in the late 2020s. The Axiom 3 mission lifted off from Kennedy Space Center's Pad 39A on Jan. 18, 2024. It was the first spaceflight entirely with European citizens.
Yahoo
an hour ago
- Yahoo
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a 'Future Ready' symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). The presentation/posters planned at ADA's 85th Scientific Sessions regarding the most recent advances in inhaled insulin treatment include: Symposium – Future Ready – Breakthrough in Pediatric Type 1 Diabetes Care Sunday, June 22 – 1:30 to 3:00 p.m. (Central) in Room W 181(A-C)Dr. Michael J. Haller will present: From Discovery to Treatment – Latest Updates on Inhaled Insulin Treatment Patient Reported Outcomes with Use of Inhaled Technosphere Insulin (T1) (Board 827)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. Peter Calhoun Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM – Results from a Phase III Clinical Trial from India (Board No. 833)Saturday, June 21, 2025 – 12:30 to 1:30 p.m. (Central) Presenter: Dr. K M Prasanna Kumar Additionally, MannKind will host booth #1617 in the Exhibit Hall throughout the ADA's Scientific Sessions. Members of MannKind's Medical Education Team will be available for scientific exchange in the medical section of the booth. For more information about ADA's Scientific Sessions programming, and/or to register to attend the conference, please visit: MannKind expects to issue the topline results from the full study pediatric data set with safety extension in 2Q 2025 and anticipates submitting a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication for Afrezza. About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking StatementsThis press release contains forward-looking statements about a planned release of scientific data and a potential sBLA submission for Afrezza that involves risks and uncertainties. Words such as 'believes', 'anticipates', 'plans', 'expects', 'intends', 'will', 'goal', 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the preparation of data releases and filings may subject us to unanticipated delays as well as other risks detailed in MannKind's filings with the Securities and Exchange Commission, including under the 'Risk Factors' heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. CONTACT: MannKind Contacts: Media Relations Christie Iacangelo, (818) 292-3500 Email: media@ Investor Relations Ana Kapor, (818) 661-5000 Email: ir@ in to access your portfolio
